US/UK/Canada

Share

Contacts

  • Mark Waugh

    CEO


    +1 (260) 804-1342

    • Links

    Pick a time period -
    Tags ( Active)

    24-month follow up data from the clinical study of OssDsign Catalyst® show 100% spinal fusion

    Uppsala, April 9, 2025. OssDsign AB (publ.) today announces that the 24-month follow up results from the clinical study TOP FUSION will be published in the peer-reviewed journal, Biomedical Journal of Scientific & Technical Research. The results demonstrate a 100% spinal fusion rate and improved quality of life and pain after surgery with the innovative nanosynthetic bone graft OssDsign Catalyst.The data, soon to be published in the peer-reviewed journal, Biomedical Journal of Scientific & Technical Research, demonstrates that using OssDsign Catalyst leads to consistent and rapid bone

    First patient included in OssDsign’s clinical study of the synthetic bone graft OssDsign Catalyst

    Uppsala, 8 September 2021 - OssDsign AB (publ) today announced that the first patient has been included in the company’s clinical study TOP FUSION to investigate the long-term safety and efficacy of OssDsign Catalyst in patients undergoing spinal fusion surgery. The study will be conducted at the National Center for Spinal Disorders under the leadership of Dr Péter Pál Varga and Dr Áron Lazary.OssDsign Catalyst is a market cleared synthetic bone graft based on a patented nanocrystalline solution that stimulates the formation of healthy bone tissue. Data from a recently published pre-

    OssDsign reports successful outcome at 6-month follow-up of clinical study on sinus augmentation

    OssDsign AB (publ) today announced positive interim results from a clinical study titled: “Safety and performance of granular calcium phosphate in augmentation of the maxillary sinus floor”. This study represents the first use of OssDsign’s proprietary calcium phosphate material in the oral cavity.As previously communicated, OssDsign has been sponsoring a clinical investigation of the safety and performance of the company’s proprietary calcium phosphate material to support bone growth in augmentation of the maxillary sinus floor. This open evaluation study is being performed on 20

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media